Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,524.40GBp
18 Apr 2019
Change (% chg)

-16.40 (-1.06%)
Prev Close
1,540.80
Open
1,526.80
Day's High
1,536.20
Day's Low
1,523.20
Volume
5,924,105
Avg. Vol
7,769,127
52-wk High
1,648.80
52-wk Low
1,395.80

About

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare... (more)

Overall

Beta: 0.98
Market Cap(Mil.): £76,031.63
Shares Outstanding(Mil.): 4,987.64
Dividend: 23.00
Yield (%): --

Financials

  GSK.L Industry Sector
P/E (TTM): 20.22 57.23 57.80
EPS (TTM): 0.75 -- --
ROI: 13.34 12.21 11.82
ROE: 174.65 13.15 12.64

GSK wins U.S. nod for two-drug HIV combination

GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

Apr 08 2019

UPDATE 2-GSK wins U.S. nod for two-drug HIV combination

April 8 GlaxoSmithKline Plc's two-drug treatment for HIV infections won U.S. market approval on Monday, boosting the British drugmaker's growth prospects against competitor Gilead Sciences Inc.

Apr 08 2019

U.S. FDA approves GSK's two-drug HIV treatment

April 8 The U.S. Food and Drug Administration said on Monday it had approved GlaxoSmithKline Plc's two-drug HIV treatment.

Apr 08 2019

GSK fights to subpoena publisher of Zofran study by plaintiffs’ consultant

GlaxoSmithKline PLC is fighting a bid to block it from subpoenaing a medical journal that published a study linking the use of the anti-nausea drug Zofran during pregnancy to birth defects that the company says was funded by plaintiffs' lawyers.

Apr 03 2019

GSK reports positive data for experimental blood cancer drug

GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

Mar 21 2019

GSK reports positive data for experimental blood cancer drug

March 21 GlaxoSmithKline received a boost for its oncology research on Thursday, as it reported further positive data from a study of its experimental drug for blood cancer.

Mar 21 2019

GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

Mar 19 2019

GSK reports positive data from trial of endometrial cancer drug

March 19 GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

Mar 19 2019

GSK accuses Zofran plaintiffs' law firms of funding academic study

A lawyer for GlaxoSmithKline PLC on Tuesday accused plaintiffs' lawyers of financially backing a study published last year reporting an increased risk of birth defects for children born to women who used the antinausea drug Zofran during pregnancy.

Mar 05 2019

British fraud office abandons Rolls-Royce, GSK investigations

LONDON The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".

Feb 22 2019

Earnings vs. Estimates